SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

electroCore Highlights Publication Of Paper 'Non-invasive vagus nerve stimulation for primary headache: a clinical update' In 'Cephalalgia'

electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagus nerve stimulation for primary headache: a clinical

Benzinga · -

electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagus nerve stimulation for primary headache: a clinical update,”1 in Cephalalgia, the official journal of the International Headache Society (IHS).

The paper is a narrative review of recent scientific and clinical research into non-invasive vagus nerve stimulation (nVNS) for headache, including findings from mechanistic studies and their possible relationships to the clinical effects of nVNS. The review concludes that scientific and clinical studies support the emergence of nVNS as an effective, safe, well-tolerated, and practical treatment for primary headache disorders and supports the consideration of nVNS as: (1) a first-line treatment for both the acute and preventive treatment of cluster headache; (2) an effective option for acute treatment of migraine; and (3) a highly relevant, practical option for migraine preventive therapy.

“We are pleased with the scientific review and clinical recommendations made by the authors of this clinical update and hope that these recommendations, which we believe support the use of gammaCore™ (nVNS) in the treatment of both cluster and migraine headache, will help drive awareness of this novel technology by physicians and patients alike,” said Peter Staats, MD, Chief Medical Officer of electroCore.

Eric Liebler, Senior Vice President, Neurology at electroCore, and a co-author of the paper, commented, “The growing understanding of the first line role of nVNS for the treatment of cluster headache and its ability to be used acutely and preventively in migraine and cluster headache is a credit to the quality of the basic science and clinical trials that support these treatment recommendations.”

Dr. Stephen Silberstein, past President the American Headache Society, Director of the Jefferson Headache Center at the Thomas Jefferson University Medical Center, and the first author of the paper, commented, “Over the past several years the basic science and clinical evidence from studies completed across the United States and Europe have shown us not only the clinical benefit of nVNS but how and why it may be working in those patients. The interplay and overlap of the many ways nVNS affects the brain supports its ability to be used as a preventive and acute treatment for both cluster and migraine headache. Neuromodulation is a tool that we feel should be available to our cluster and migraine headache patients who need it.”

The paper is available via open access at: https://journals.sagepub.com/doi/full/10.1177/0333102420941864